文献速递眼底病与葡萄膜炎

贝伐珠单抗反应不佳与AMD房水中较高IL-6和IL-8细胞因子相关

Poor Response to Bevacizumab Correlates With Higher IL-6 and IL-8 Aqueous Cytokines in AMD.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2024-01-01

研究纳入33例未治疗的新生血管性年龄相关性黄斑变性(nAMD)患者,接受贝伐珠单抗玻璃体腔注射负荷剂量(6周间隔共3次),检测基线、第6周和第12周房水12种炎症细胞因子。第12周按黄斑中心凹厚度(CST)变化分组:应答组27例CST下降,反应不佳组6例CST未下降。结果显示仅房水IL-8在两组间有显著差异,反应不佳组第12周IL-8更高;房水IL-6和IL-8与CST呈正相关(Spearman r分别为0.45和0.55);贝伐珠单抗治疗期间细胞因子浓度总体呈时间性升高。

要点

  • 仅房水IL-8在应答组与反应不佳组间有显著差异,反应不佳组第12周IL-8更高。
  • 房水IL-6和IL-8与SD-OCT测得的CST呈正相关(Spearman r=0.45和0.55)。
  • 贝伐珠单抗治疗期间细胞因子浓度总体呈时间性升高。

核心结论

  • 房水IL-6和IL-8可能是nAMD治疗反应或反应不佳的重要标志物。
  • 未来治疗策略可能包括对单用抗VEGF治疗无反应的患者联合靶向VEGF和IL-6和/或IL-8的治疗。

研究设计与样本

  • 研究纳入33例未治疗的新生血管性年龄相关性黄斑变性(nAMD)患者,接受贝伐珠单抗玻璃体腔注射负荷剂量:6周间隔共3次注射。
  • 在第1次(基线)、第2次(第6周)和第3次(第12周)注射前采集房水样本,分析12种炎症细胞因子水平。
  • 根据第12周谱域光学相干断层扫描(SD-OCT)测得的黄斑中心凹厚度(CST)变化分组:第1组为CST下降者(应答者,n=27),第2组为CST未下降者(反应不佳者,n=6)。

主要发现

  • 房水IL-8是唯一在应答者与反应不佳者之间水平有显著差异的细胞因子,反应不佳组第12周IL-8更高。
  • 房水IL-6和IL-8水平与SD-OCT测得的CST呈正相关(Spearman r分别为0.45和0.55)。
  • 贝伐珠单抗治疗期间细胞因子浓度总体呈时间性升高。

关键数值与推荐

  • 应答者定义为第12周SD-OCT上CST下降(n=27);反应不佳者定义为第12周CST未下降(n=6)。
  • 房水IL-6与CST的Spearman相关系数r=0.45;房水IL-8与CST的Spearman相关系数r=0.55。

临床怎么用

  • 作者认为房水IL-6和IL-8可能是nAMD治疗反应或反应不佳的重要标志物。
  • 作者提出未来治疗策略可能包括对单用抗VEGF治疗无反应的患者联合靶向VEGF和IL-6和/或IL-8的治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the effect of intravitreal bevacizumab on aqueous levels of a panel of 12 inflammatory cytokines in patients with neovascular age-related macular degeneration (nAMD) and correlate response to treatment, as measured by change in the central subfovea thickness (CST), with cytokine levels. METHODS: Thirty-three treatment-naïve patients with nAMD received a loading dose of intravitreal bevacizumab consisting of three injections at six weekly intervals. The aqueous samples prior to the first (baseline), second (week 6), and third (week 12) injections were analyzed for cytokine levels. Participants were subgrouped based on changes in CST on spectral-domain optical coherence tomography (SD-OCT) at 12 weeks. Group 1 included patients with a decrease in CST (responders; n = 27). Group 2 included patients who had no decrease in CST (poor responders; n = 6). RESULTS: Aqueous IL-8 was the only cytokine to demonstrate a significant difference in levels between responders and poor responders, with higher interleukin-8 (IL-8) at week 12 in the poor responder group. Aqueous IL-6 and IL-8 levels showed a positive correlation with CST on SD-OCT (Spearman r = 0.45 and 0.55, respectively). There was a temporal increase overall in cytokine concentration accompanying bevacizumab treatment. CONCLUSIONS: Aqueous IL-6 and IL-8 may be important markers of treatment response or poor response in nAMD. Future therapeutic strategies may include targeted treatment against both vascular endothelial cell growth factor (VEGF) and IL-6 and/or IL-8 in patients who do not respond to anti-VEGF treatment alone.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Connolly E, El-Farouki G, Brennan K, et al. Poor Response to Bevacizumab Correlates With Higher IL-6 and IL-8 Aqueous Cytokines in AMD. Invest Ophthalmol Vis Sci. 2024. PMID: 39325472. doi:10.1167/iovs.65.11.37

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。